[go: up one dir, main page]

MX2007010962A - Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. - Google Patents

Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.

Info

Publication number
MX2007010962A
MX2007010962A MX2007010962A MX2007010962A MX2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A
Authority
MX
Mexico
Prior art keywords
rapamycin
combination
myxoma virus
therapeutic treatment
cells
Prior art date
Application number
MX2007010962A
Other languages
English (en)
Inventor
Grant Mcfadden
John Barrett
Marianne Stanford
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of MX2007010962A publication Critical patent/MX2007010962A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere al uso terapeutico de una combinacion del virus Myxoma, inclusive en combinacion con rapamicina. El tratamiento con rapamicina aumenta la capacidad del virus Myxoma para infectar selectivamente las celulas que tienen una respuesta antiviral innata deficiente, inclusive las celulas que no son sensibles al interferon. La combinacion de rapamicina y el virus Myxoma puede utilizarse para tratar enfermedades caracterizadas por la presencia de estas celulas, inclusive cancer. La invencion tambien se refiere al uso terapeutico del virus Myxoma que no expresa la proteina funcional M135R. La figura mas representativa de la invencion es la numero 31.
MX2007010962A 2005-03-07 2006-03-06 Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. MX2007010962A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
PCT/CA2006/000315 WO2006094385A1 (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Publications (1)

Publication Number Publication Date
MX2007010962A true MX2007010962A (es) 2008-03-10

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010962A MX2007010962A (es) 2005-03-07 2006-03-06 Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.

Country Status (14)

Country Link
US (5) US20090035276A1 (es)
EP (2) EP1863906A4 (es)
JP (2) JP2008531739A (es)
KR (1) KR101479093B1 (es)
CN (2) CN101137748B (es)
AU (1) AU2006222500B2 (es)
CA (1) CA2600675C (es)
DK (1) DK2388315T3 (es)
IL (2) IL185376A0 (es)
MX (1) MX2007010962A (es)
NZ (2) NZ577283A (es)
RU (1) RU2461630C2 (es)
UA (1) UA96412C2 (es)
WO (1) WO2006094385A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96412C2 (ru) 2005-03-07 2011-11-10 Робартс Рисерч Инститьют Применение комбинации вируса миксомы и рапамицина для лечения
KR20090014364A (ko) 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
KR101585702B1 (ko) * 2008-05-22 2016-01-15 제일약품주식회사 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2012171007A2 (en) * 2011-06-09 2012-12-13 University Of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
SG11202101291VA (en) 2018-08-08 2021-03-30 Univ Arizona State Method for improved poxvirus yields
MX2021002668A (es) * 2018-09-05 2021-05-12 Univ Arizona State Plataforma de virus oncolitico para tratar el cancer hematologico.
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
CA3157511A1 (en) * 2019-10-10 2021-04-15 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
CA2296319A1 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
NZ503664A (en) 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
WO2001004318A2 (en) * 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
WO2001035970A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AU2003258168B2 (en) * 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
UA80756C2 (en) * 2003-04-22 2007-10-25 Wyeth Corp Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
US20050019308A1 (en) * 2003-07-07 2005-01-27 Oncolytics Biotech Inc. Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
CA2562904C (en) * 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
UA96412C2 (ru) 2005-03-07 2011-11-10 Робартс Рисерч Инститьют Применение комбинации вируса миксомы и рапамицина для лечения

Also Published As

Publication number Publication date
JP2008531739A (ja) 2008-08-14
EP2388315A3 (en) 2012-05-02
AU2006222500B2 (en) 2011-09-01
WO2006094385A1 (en) 2006-09-14
RU2007137008A (ru) 2009-04-20
IL208070A0 (en) 2010-12-30
CA2600675A1 (en) 2006-09-14
EP1863906A4 (en) 2009-06-03
US20110195050A1 (en) 2011-08-11
US20140134134A1 (en) 2014-05-15
US20130171106A1 (en) 2013-07-04
DK2388315T3 (da) 2014-08-25
JP2012236860A (ja) 2012-12-06
EP1863906A1 (en) 2007-12-12
CA2600675C (en) 2015-12-15
RU2461630C2 (ru) 2012-09-20
EP2388315B1 (en) 2014-05-21
EP2388315A2 (en) 2011-11-23
AU2006222500A1 (en) 2006-09-14
KR101479093B1 (ko) 2015-01-26
JP5674210B2 (ja) 2015-02-25
NZ577283A (en) 2010-11-26
KR20070110423A (ko) 2007-11-16
IL185376A0 (en) 2008-02-09
US9987315B2 (en) 2018-06-05
CN101137748A (zh) 2008-03-05
HK1163175A1 (en) 2012-09-07
NZ560840A (en) 2009-07-31
CN102357104A (zh) 2012-02-22
CN101137748B (zh) 2011-12-14
US20090035276A1 (en) 2009-02-05
CN102357104B (zh) 2016-01-27
US20180256656A1 (en) 2018-09-13
UA96412C2 (ru) 2011-11-10
IL208070A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
PL2155758T3 (pl) Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
TW200732347A (en) VEGF analogs and methods of use
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
MX2007010962A (es) Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
WO2008127710A3 (en) Methods for treating cancer resistant to erbb therapeutics
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
MY144616A (en) Substituted dihydroquinazolines
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
MX2010005107A (es) Componente de silibinina para tratamiento contra hepatitis.
MX2021008036A (es) Bioplaguicidas para la enfermedad tizon tardio de la papa.
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2007076161A3 (en) Compounds with therapeutic activity
MX2010004892A (es) Terapia de combinacion para tratar infecciones virales persistentes.
PH12021552677A1 (en) Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases
WO2006078284A3 (en) Methods and compositions related to antiviral therapy using algae and cyanobacteria
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
SG155898A1 (en) Treatment of diseases using nalmefene and its analogs
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP2021023A4 (en) MYXOM VIRUS MUTANTS FOR CANCER TREATMENT
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
IN2011KN02819A (es)

Legal Events

Date Code Title Description
FG Grant or registration